The abstract is read at the publisher; the summary is JClub's.
Tinengotinib showed clinical benefit in 27.0% of evaluable patients with advanced solid tumors, with antitumor activity strongest at 10 mg and 12 mg once daily.
- Why it matters: The study addresses the need for safer, biomarker-informed therapies for advanced metastatic solid tumors lacking standard options, while clarifying response and resistance signals.
- What they did: In a multicenter phase Ib/II trial (NCT04742959) across 7 U.S. sites, 197 patients received tinengotinib at 12 mg once daily (arm A) or other dose levels (arm C), with safety, PK, and exploratory genomic and ctDNA analyses.
- The result: Treatment-related adverse events occurred in 81.2% of patients, with hypertension most common and hyperphosphatemia/ocular toxicities uncommon; FGFR2 fusions in cholangiocarcinoma responders and ctDNA variant allele frequency reductions supported target engagement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.